tesaglitazar has been researched along with bromodeoxyuridine in 1 studies
| Studies (tesaglitazar) | Trials (tesaglitazar) | Recent Studies (post-2010) (tesaglitazar) | Studies (bromodeoxyuridine) | Trials (bromodeoxyuridine) | Recent Studies (post-2010) (bromodeoxyuridine) |
|---|---|---|---|---|---|
| 74 | 13 | 25 | 13,164 | 71 | 1,816 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersson, U; Bamberg, K; Berg, AL; Blomgren, B; Camejo, G; Dahl, B; Dillner, B; Elebring, M; Evans, J; Hellmold, H; Holland, T; Lundholm, E; Roberts, R; Sjögren, N; Skånberg, I; Tugwood, J; Westerberg, R; Zhang, H | 1 |
1 other study(ies) available for tesaglitazar and bromodeoxyuridine
| Article | Year |
|---|---|
Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats.
Topics: Alkanesulfonates; Animals; Antimetabolites; Bromodeoxyuridine; Cholesterol; DNA; DNA Replication; Female; Fibrosarcoma; Hypoglycemic Agents; Immunohistochemistry; Male; Mesoderm; Microdissection; Organ Size; Phenylpropionates; PPAR alpha; PPAR gamma; Protein Binding; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA; Skin Neoplasms; Triglycerides | 2007 |